Every 424B that Cadrenal Therapeutics, Inc. (CVKD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CVKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVKD filings page.
Cadrenal Therapeutics, Inc. is registering for resale up to 2,942,400 shares of common stock for existing holders of warrants issued in a July 1, 2026 private investment in public equity (PIPE) and related placement agent compensation. The company itself is not selling any shares under this prospectus and receives no proceeds from stockholder resales.
The registered shares consist of 2,880,000 shares issuable on exercise of pre-funded and Series C-1/C-2 warrants sold to a single institutional investor and 62,400 shares issuable on exercise of placement agent warrants. If all investor and placement agent warrants are exercised for cash, Cadrenal would receive about $6.0 million, intended for working capital and general corporate purposes, in addition to the approximately $3.0 million gross proceeds already received in the PIPE.
Common stock outstanding was 3,098,592 shares as of July 10, 2026, and would be 6,040,992 shares if all related warrants are fully exercised. The company highlights significant financing needs, potential dilution, substantial resale volume (up to roughly half of current shares), warrant-related constraints, and an auditor’s going concern explanatory paragraph as key risks.
Cadrenal Therapeutics, Inc. is registering 1,180,003 shares of Common Stock for resale by selling stockholders, consisting of 1,142,860 shares issuable upon exercise of Investor Warrants and 37,143 shares issuable upon exercise of Placement Agent Warrants. The company will not receive proceeds from resales but will receive proceeds from any cash exercises of those warrants.
The registration fulfills contractual registration rights under an inducement agreement related to a private placement and warrants issued April 1, 2026; resales may occur in public or private transactions at prevailing or negotiated prices.
Cadrenal Therapeutics registered 590,001 shares of Common Stock for resale under a prospectus supplement to its Form S-3 registration statement. The supplement states that 571,430 of those shares are issuable upon exercise of Existing Warrants that were amended on March 31, 2026 to reduce the exercise price from $16.50 to $4.50. The supplement covers resale "from time to time," and the prospectus remains qualified by the underlying Form S-3 prospectus.
The company reports a Nasdaq closing price of $5.12 per share as of March 31, 2026. The supplement updates warrant terms and registers the related shares; other prospectus terms continue to apply.
Cadrenal Therapeutics is issuing 207,374 shares of common stock in a registered direct offering at $10.85 per share, for gross proceeds of $2,250,007.90. In a concurrent private placement, the same investors receive unregistered common warrants to buy up to 414,748 additional shares at an exercise price of $10.60 per share.
The company expects net proceeds of approximately $1.9 million, which it plans to use for working capital and general corporate purposes. After the offering, 2,338,127 shares of common stock will be outstanding, and new investors will see immediate dilution of $8.44 per share based on an as adjusted pro forma net tangible book value of $2.41. Cadrenal also discloses that its limited capital and financing needs raise substantial doubt about its ability to continue as a going concern without further funding.
CVKD is updating its at-the-market common stock offering program under an existing shelf registration. The company has sold an aggregate of $10,005,300 of common stock through its sales agreement with H.C. Wainwright & Co. as of this prospectus supplement. This update reduces the amount available under the November 18, 2025 prospectus supplement by $2,250,007.90, leaving $569,717 of common stock that can still be sold under that supplement. CVKD’s common stock trades on the Nasdaq Capital Market under the symbol CVKD, and the last reported sale price was $11.00 per share on December 12, 2025.
Cadrenal Therapeutics, Inc. is updating its at-the-market equity program to offer and sell up to $3,438,062 of common stock through H.C. Wainwright & Co. as sales agent or principal. Based on an assumed price of $11.61 per share, this corresponds to up to 296,129 shares, which would raise Cadrenal’s common stock outstanding from 2,075,845 to as many as 2,371,974 shares if fully sold. Wainwright will receive a 3.0% sales commission on gross proceeds. The company plans to use any net proceeds for working capital and general corporate purposes, including potential acquisitions, licensing or investments in product candidates or other intellectual property, and possible repurchases of securities. The filing highlights that the ATM structure may lead to price variation and potential dilution for new and existing shareholders.